Loading
A phase 2 trial of Siltuximab and Melphalan in Multiple myeloma, run by Memorial Sloan Kettering Cancer Center, now recruiting.
A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant is a phase 2 interventional study registered as NCT06679829 by Memorial Sloan Kettering Cancer Center, with 215 participants planned, started 2024-11-06 and due to reach its primary completion in 2027-11. Interventions recorded: Siltuximab, Melphalan. Conditions recorded: Multiple Myeloma.
Linked to the drug Siltuximab because the registry names it among its interventions and Multiple myeloma among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Siltuximab, Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Melphalan (including hepatic delivery system) and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/